瓦米费波特:第一种口服费罗波丁抑制剂的专著
Federica Pilo1, Emanuele Angelucci2
1Hematology and Transplant Center, Azienda Ospedaliera Brotzu, 09121 Cagliari, Italy.
Journal of clinical medicine
|September 28, 2024
概括
口服费罗波丁抑制剂Vamifeport通过向肝丁-费罗波丁轴,在治疗无效的红色素形成方面表现有前途. 它改善了状细胞疾病模型的结果,并正在针对血病进行调查.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 具有无效红色素形成的先天性疾病涉及复杂的调节机制.
- 肝素-费洛波丁轴对系统铁平衡至关重要,也是关键的治疗点.
- 目前的疗法旨在调节红色素形成调节器,重点关注铁代谢.
研究的目的:
- 评估 vamifeport,一种口服费罗波丁抑制剂,作为一种用于无效红色素形成的新型治疗剂.
- 调查向肝素-费罗波丁轴治疗与铁相关的血液学疾病的疗效.
- 建立一个在状细胞疾病模型中为 vamifeport 的临床前概念验证.
主要方法:
- 利用 Townes 状细胞病 (SCD) 的小鼠模型进行临床前评估.
- 口服的 vamifeport 用于评估其对红色受体和铁平衡的影响.
- 在患有SCD,非输血依赖性 (NTD) thalassemia和输血依赖性 (TD) thalassemia的患者中启动的临床试验.
主要成果:
- 在SCD小鼠模型中,Vamifeport治疗降低了红细胞血红蛋白度和血管内血解.
- 该药物减少了炎症,改善了血液动力学,并在临床前研究中预防了血管封闭性危机.
- 在NTD血症患者的初步数据表明, vamifeport在降低铁含量方面的安全性和有效性.
结论:
- 瓦米费波特显示出作为一种新型治疗药物的潜力,该药物针对无效红色素形成的肝-费洛波丁轴.
- 与现有的治疗方法相比,该药物通过直接调节费罗波丁,提供了独特的作用机制.
- 进一步的研究正在进行中,以确定 vamifeport 在临床环境中作为独立治疗的疗效.
相关概念视频
The Early Endosome: Endocytosis of Transferrin
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


